IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 30.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,528 shares of the medical research company's stock after purchasing an additional 2,488 shares during the quarter. NEOS Investment Management LLC's holdings in IQVIA were worth $2,069,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the fourth quarter worth about $33,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $44,000. Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after acquiring an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA in the fourth quarter worth $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 0.6 %

NYSE:IQV traded down $1.12 during trading hours on Monday, reaching $176.28. 2,234,715 shares of the company were exchanged, compared to its average volume of 1,303,021. IQVIA Holdings Inc. has a 52-week low of $169.54 and a 52-week high of $253.84. The stock has a 50 day simple moving average of $193.15 and a 200 day simple moving average of $206.05. The firm has a market cap of $31.08 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Truist Financial reaffirmed a "buy" rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Barclays dropped their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, William Blair reiterated an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.